Skip to main content
VISIT JANSSEN GLOBAL
 
 
 

EMEA
change location▼

Search
Search

Welcome to Janssen Europe, Middle-East and Africa

VISIT JANSSEN GLOBAL

Janssen EMEA › Media Center

Media Center

The Media Center is intented to provide resources for media professionals only. It is not inteded for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Dec 02, 2019

Janssen Receives EU Marketing Authorisation for Darzalex®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Nov 26, 2019

International HIV Experts Call for Focus on Quality of Life Beyond Viral Suppression    

Nov 12, 2019

TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies 

Oct 23, 2019

Janssen Seeks to Expand Use of TREMFYA®▼ (guselkumab) in the Treatment of Adults with Active Psoriatic Arthritis

Oct 21, 2019

CHMP Grants Positive Opinion for Expanded Use of Janssen’s Darzalex®▼(daratumumab) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Oct 21, 2019

STELARA® (USTEKINUMAB) DATA DEMONSTRATE LONG-TERM EFFICACY AND SAFETY RESULTS IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN PHASE 3 EXTENSION TRIAL

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

Stelara MOA infographic

The Role Of The Immune System In Crohn’s Disease

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL